SVB Wealth’s Arcus Biosciences RCUS Stock Holding History

SVB Wealth’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,000	Closed	-$562K	–	1017
2021 Q1	$562K	Buy	+20,000	New	+$696K	0.01%	487

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

SVB Wealth's RCUS Position: Q2 2021 in Review

SVB Wealth sold out of Arcus Biosciences (RCUS) in Q2 2021, closing a stake of 20,000 shares — an estimated $562K sold.

SVB Wealth first reported a position in RCUS in Q1 2021 and held it in 1 quarter. The position peaked at $562K in Q1 2021. 130 funds tracked by Wall St. Rank hold RCUS as of Q2 2021.

SVB Wealth reported no remaining Arcus Biosciences position as of Q2 2021 after selling out during the quarter.
SVB Wealth sold 20,000 Arcus Biosciences shares in Q2 2021, an estimated $562K.
SVB Wealth first reported a position in Arcus Biosciences in Q1 2021 and held it in 1 quarter.
SVB Wealth's Arcus Biosciences position peaked at $562K in Q1 2021.
130 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2021.

Based on SVB Wealth's 13F filing for Q2 2021, filed 13 Aug 2021.